Browsing: Madrigal

Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors

By 0

The race to treat obesity and diabetes is shifting again after Eli Lilly pushed back approval plans for its next-generation obesity drug, retatrutide, to Q1 2027, even as phase 3 data showed weight loss of up to 22.6% and blood sugar benefits. This mix of regulatory delay and clinical progress can reshape expectations for companies…